Stem Cell Therapy for Heart Failure
Abstract
Despite a lot of advancesin current therapeutic modalities, heart failure and coronary artery disease are still the leading cause of morbidity and mortality. Current management of heart failure indeed increase survival rate, however re-hospitalization and mortality rate remain high. Furthermore, none of those therapeutic modalitiesare based on myocardial regeneration concept.Stem cell therapy is an interesting new concept in heart failure management. Various cell types, administration route and cell expansions strategies are extensively studied. Stem cell improve myocardial perfusion and differentiate into angiogenic and contractile cell. Stem cell therapy is a promising regeneratif medicine in the future.
Downloads
Download data is not yet available.
References
Li SC, Wang L, Jiang H, Acevedo J, Chang AC, Loudon WG. Stem cell engineering for treatment of heart diseases: potentials and challenges. Cell Biol Int 2009;33:255-67.
Ortak J, Akin I, Kische S, Nienaber CA, Ince H. Stem cell use for cardiac diseases as of 2008. Transfus Apher Sci 2008;38:253-60.
Zimmermann WH, Didie M, Doker S, et al. Heart muscle engineering: an update on cardiac muscle replacement therapy. Cardiovasc Res 2006;71:419-29.
Robey PG. Stem cells near the century mark. J Clin Invest 2000;105:1489-91.
Slack JM. Stem cells in epithelial tissues. Science 2000;287:1431-3.
Orlic D, Kajstura J, Chimenti S, et al. Bone marrow cells re-generate infarcted myocardium. Nature 2001;410:701-5.
Murry CE, Soonpaa MH, Reinecke H, et al. Haematopoietic stem cells do not transdifferentiate into cardiac myocytes in myocardial infarcts. Nature 2004;428:664-8.
Burlacu A, Rosca AM, Maniu H, et al. Promoting effect of 5-azacytidine on the myogenic differentiation of bone marrow stromal cells. Eur J Cell Biol 2008;87:173-84.
Antonitsis P, Ioannidou-Papagiannaki E, Kaidoglou A, et al. Car-diomyogenic potential of human adult bone marrow mesenchy-mal stem cells in vitro. Thorac Cardiovasc Surg 2008;56:77-82.
Yang L, Soonpaa MH, Adler ED, et al. Human cardiovascular progenitor cells develop from a KDR+ embryonic-stem-cell-derived population. Nature 2008;453:524-8.
Dimmeler S, Burchfield J, Zeiher AM. Cell-based therapy of myocardial infarction. Arterioscler Thromb Vasc Biol 2008;28:208-16.
Stagg MA, Coppen SR, Suzuki K, et al. Evaluation of frequency, type, and function of gap junctions between skeletal myoblasts overexpressing connexin43 and cardiomyocytes: relevance to cell transplantation. FASEB J 2006;20:744-6.
Leobon B, Garcin I, Menasche P, Vilquin JT, Audinat E, Char-pak S. Myoblasts transplanted into rat infarcted myocardium are functionally isolated from their host. Proc Natl Acad Sci U S A 2003;100:7808-11.
van Vliet P, Roccio M, Smits AM, et al. Progenitor cells isolated from the human heart: a potential cell source for regenerative therapy. Neth Heart J 2008;16:163-9.
Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripo-tent stem cells from adult human fibroblasts by defined factors. Cell 2007;131:861-72.
Jolicoeur EM, Granger CB, Fakunding JL, et al. Bringing car-diovascular cell-based therapy to clinical application: perspectives based on a National Heart, Lung, and Blood Institute Cell Therapy Working Group meeting. Am Heart J 2007;153:732-42.
Ortak J, Akin I, Kische S, Nienaber CA, Ince H. Stem cell use for cardiac diseases as of 2008. Transfus Apher Sci 2008;38:253-60.
Zimmermann WH, Didie M, Doker S, et al. Heart muscle engineering: an update on cardiac muscle replacement therapy. Cardiovasc Res 2006;71:419-29.
Robey PG. Stem cells near the century mark. J Clin Invest 2000;105:1489-91.
Slack JM. Stem cells in epithelial tissues. Science 2000;287:1431-3.
Orlic D, Kajstura J, Chimenti S, et al. Bone marrow cells re-generate infarcted myocardium. Nature 2001;410:701-5.
Murry CE, Soonpaa MH, Reinecke H, et al. Haematopoietic stem cells do not transdifferentiate into cardiac myocytes in myocardial infarcts. Nature 2004;428:664-8.
Burlacu A, Rosca AM, Maniu H, et al. Promoting effect of 5-azacytidine on the myogenic differentiation of bone marrow stromal cells. Eur J Cell Biol 2008;87:173-84.
Antonitsis P, Ioannidou-Papagiannaki E, Kaidoglou A, et al. Car-diomyogenic potential of human adult bone marrow mesenchy-mal stem cells in vitro. Thorac Cardiovasc Surg 2008;56:77-82.
Yang L, Soonpaa MH, Adler ED, et al. Human cardiovascular progenitor cells develop from a KDR+ embryonic-stem-cell-derived population. Nature 2008;453:524-8.
Dimmeler S, Burchfield J, Zeiher AM. Cell-based therapy of myocardial infarction. Arterioscler Thromb Vasc Biol 2008;28:208-16.
Stagg MA, Coppen SR, Suzuki K, et al. Evaluation of frequency, type, and function of gap junctions between skeletal myoblasts overexpressing connexin43 and cardiomyocytes: relevance to cell transplantation. FASEB J 2006;20:744-6.
Leobon B, Garcin I, Menasche P, Vilquin JT, Audinat E, Char-pak S. Myoblasts transplanted into rat infarcted myocardium are functionally isolated from their host. Proc Natl Acad Sci U S A 2003;100:7808-11.
van Vliet P, Roccio M, Smits AM, et al. Progenitor cells isolated from the human heart: a potential cell source for regenerative therapy. Neth Heart J 2008;16:163-9.
Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripo-tent stem cells from adult human fibroblasts by defined factors. Cell 2007;131:861-72.
Jolicoeur EM, Granger CB, Fakunding JL, et al. Bringing car-diovascular cell-based therapy to clinical application: perspectives based on a National Heart, Lung, and Blood Institute Cell Therapy Working Group meeting. Am Heart J 2007;153:732-42.
Views & Downloads
Abstract views: 4039
PDF (Bahasa Indonesia) downloads: 3965
PDF (Bahasa Indonesia) downloads: 3965
How to Cite
Pratama, V., & Yuniadi, Y. (1). Stem Cell Therapy for Heart Failure. Indonesian Journal of Cardiology, 33(5), 50-4. https://doi.org/10.30701/ijc.v33i5.76
Section
Review Article
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
